Ascletis Pharma, Inc. (HK:1672) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Ascletis Pharma’s new weight loss drug candidate, ASC47, combined with semaglutide, has shown promising results in preclinical trials, achieving more significant weight reduction and muscle preservation compared to semaglutide alone. The combination treatment demonstrated a 36.2% total body weight reduction in obese mice, outperforming the 23.1% reduction observed with semaglutide monotherapy. With ongoing Phase I trials in Australia showing good tolerability, this development could be a significant advancement in obesity treatment.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple and Nvidia Partner to Enable Faster LLM Token Generation
- Amazon Faces Largest Teamsters Strike to Date in Busy Christmas Season
- ‘Time to Move to the Sidelines,’ Says Analyst About Rivian Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
